Israeli Biotech Scientists Company Claim To Cure Cancer Within A Year

Israeli Biotech Scientists Company Claim To Cure Cancer Within A Year

Israeli Biotech Scientists Company Claim To Cure Cancer Within A Year

Israeli Biotech Scientists Company Claim To Cure Cancer Within A Year.

Scientists at an Israeli biotech company say that they believe they will have a cure for cancer within a year. It revealed that they might have found the first complete cure for cancer which will be affordable, quick, and have minimal side effects but experts contacted by Live Science say that’s highly unlikely.

The scientists, from Accelerated Evolution Biotechnologies Ltd. (AEBi), told The Jerusalem Post on Jan. 28 that they “believe [they] will offer, in a year’s time, a complete cure for cancer.” But AEBi has not published its findings; instead, the public learned of the claims in the Jerusalem Post article.

According to the Post, the potential treatment is called “MuTaTo,” or “multitarget toxin.” By binding to multiple sites on a cancer cell, the treatment doesn’t give the cell enough time to mutate again before another peptide in the same mix, this one toxic to cancer cells, swoops in and eradicates the cancer, the scientists claimed.

  • I am sure You are transform by the information you  get through me, I am also sure you can be part of our daily updates. Why not leave your email behind let me keep you informed with Inspirations, Health Columns and News  always.

The researchers said they have tested their approach in mice in a single exploratory study (but their results are supposedly “consistent and repeatable”), and they hope to begin human clinical trials soon, according to the Post.

Related: Malignant Mesothelioma: Causes, Diagnosis, Mesothelioma Treatment & Get Medical Help

The claims left other scientists with doubts.

“No data to review to prove Claims”

Dr. Deanna Attai, an assistant clinical professor in the department of surgery at the University of California, Los Angeles, said that she thinks the Israeli scientists are “making a lot of leaps from what sounds like very preliminary studies.” As such, their claims are just “irresponsible,” Attai told source.

“There is no data to review,” said Dr. Robert Maki, the chief scientific officer for the Northwell Health Cancer Institute in New York. “There’s absolutely nothing to be able to look at or examine or read to know what the story is about actually.”

Adding to outside experts’ concern is that the study was conducted only in mice.

“As experience has taught us so many times, the gap from a successful mouse experiment to [an] effective, beneficial application of exciting laboratory concepts to helping cancer patients at the bedside is in fact a long and treacherous journey, filled with unforeseen and unanticipated obstacles,” wrote Dr. Len Lichtenfeld, the chief medical officer of the American Cancer Society, in a blog post responding to the Jerusalem Post story.

“Unfortunately, we must be aware that this is far from proven as an effective treatment for people with cancer, let alone a cure,” Lichtenfeld wrote.

Skepticism from industry players

Les Funtleyder, healthcare portfolio manager at E Squared Capital Management, told CNBC that the company has, to date, only tested the treatment in mice.

“It can take six to seven years to bring cancer drugs from ‘mouse to market’ – even when drugmakers receive special permissions,” said Funtleyder.

He added that AEBi has not published any clinical evidence showing the treatment works in humans.

“I mean, I’d love there to be a cure for cancer, but I do not believe them in the absence of good human evidence,” he said.

In addition, AEBi said that this cure will be effective from the first day and that the treatment will last a few weeks with no or few side effects, on the order of a “rush” or “less than a headache.”

But the claim that one treatment can cure all cancers doesn’t seem too likely, Attai said. Cancer cells express different kinds of proteins on their surfaces, so they look different to drugs and the immune system. AEBi’s treatment seems to be attacking multiple proteins on cancer cells, which perhaps may be a “promising” approach initially, she said. But past studies have shown that even if we set up a “roadblock … cancer cells kind of find a way around it,” she added.

is to say that researchers around the world wouldn’t be happy if AEBi’s treatment worked.

“We all want a cure — physicians, patients, everybody wants the cure,” Attai said. “Unfortunately, it’s just not all that simple.”